Saposin C (non-glycosylated) clinical trials
Also written BXQ-350.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses saposin C (non-glycosylated) is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Bexion Pharmaceuticals, Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test saposin C (non-glycosylated).
- Nov 2026BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaPhase 1/2 · Bexion Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses saposin C (non-glycosylated) is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- BXQ-350 in Newly Diagnosed Metastatic Colorectal CarcinomaActive, not recruitingPhase 1/2Bexion Pharmaceuticals, Inc.NCT05322590Written as BXQ-350
- BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer PatientsCompletedEarly Phase 1Bexion Pharmaceuticals, Inc.NCT05291286Written as BXQ-350
- Continued Treatment for Participants Enrolled in Studies of BXQ-350TerminatedPhase 1Bexion Pharmaceuticals, Inc.NCT04404569Written as BXQ-350
- A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)TerminatedPhase 1Bexion Pharmaceuticals, Inc.NCT04771897Written as BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
- Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid TumorsCompletedPhase 1Bexion Pharmaceuticals, Inc.NCT02859857Written as BXQ-350
- A Study of BXQ-350 in Children and Young Adults With Relapsed Solid TumorsTerminatedPhase 1Bexion Pharmaceuticals, Inc.NCT03967093Written as BXQ-350
Codes
What other systems call saposin C (non-glycosylated) · ClinicalTrials.gg INT014500
- UNII (FDA) 2N62LTC861SAPOSIN C (NON-GLYCOSYLATED)One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2N62LTC861 | SAPOSIN C (NON-GLYCOSYLATED) | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.